Q3 2025 Verrica Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Verrica Pharmaceuticals Inc (VRCA) achieved multiple commercial, corporate, scientific, and regulatory milestones in Q3 2025, providing a strong foundation for future growth.
- The company reported a 120% year-over-year increase in dispensed applicator units of YCANTH for molluscum contagiosum.
- Verrica received $18 million in cash milestone payments from its Japanese partner, Torii Pharmaceutical, in 2025, strengthening its cash position.
- The European Medicines Agency indicated no further Phase 3 clinical studies are needed for YCANTH's approval for molluscum in the EU, potentially expediting the filing process.
- Verrica's novel oncolytic peptide, VP-315, showed promising results in Phase 2 studies for basal cell carcinoma, with a 97% objective response rate and an 86% reduction in tumor size.
- The incremental growth in pull-through for YCANTH was softer in Q3 compared to the previous quarter, impacted by seasonality and competitive headwinds.
- Despite positive developments, Verrica's cash balance as of September 30, 2025, only funds operations into the late fourth quarter, indicating potential liquidity challenges.
- The company experienced a decrease in selling, general, and administrative expenses, which may reflect a reduction in sales force and commercial costs.
- Verrica's net YCANTH revenue in Q3 2025 was impacted by standard gross to net adjustments, including product returns and copay assistance program expenses.
- The timeline for filing a Marketing Authorization Application for YCANTH in the EU is extended due to procedural requirements, despite no additional clinical trials being needed.
Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals' third quarter 2025 corporate update conference call. (Operator Instructions) As a reminder, this conference is being recorded.
I will now turn the call over to our host, Kevin Gardner of Lifesci Advisors. You may begin your conference.
Thank you, operator. Hello, everyone, and welcome to Verrica Pharmaceuticals' third quarter 2025 corporate update conference call. With me on the line this morning are Jayson Rieger, President and Chief Executive Officer; Noah Rosenberg, Chief Medical Officer; John Kirby, Interim Chief Financial Officer; and David Zawitz, Chief Operating Officer.
As a reminder, during today's call, management will make forward-looking statements. These forward-looking statements are based on the company's current expectations and involve inherent risks and uncertainties. Verrica's actual results and the timing of events could differ materially from those anticipated in such forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
